Utah life sciences companies took center stage September 2, as U.S. Representative Burgess Owens (R-UT) toured Canyon Labs, Ultradent (Canyon Labs’ parent company), Ortho Development and Xenter – all innovative leaders in advancing medical technologies that improve patient care and provide jobs for hundreds of Utahns. BioUtah helped to facilitate the BioHive day. “Utah is […]
BD (Becton, Dickinson and Company) (NYSE: BDX) today announced it has completed the acquisition of Parata Systems. Parata advances BD’s transformative solutions strategy by providing a portfolio of innovative pharmacy automation solutions that power a growing network of pharmacies to reduce costs, enhance patient safety and improve the patient experience for retail, hospital and long-term care […]
The BioHive community was featured prominently at the One Utah Summit held on May 10 at the Grand America Hotel in Salt Lake City. Speakers from the life sciences industry addressed the crowd on topics ranging from job creation and talent development to life-saving innovation and drug discovery. Tom Polen, CEO of BD, and Rob […]
Recursion Co-founder and CEO, Chris Gibson, Ph.D., was honored at the One Utah Summit on May 10, receiving the Governor’s Medal for Science and Technology. Gov. Spencer Cox presented the award during the summit’s special recognition ceremony. The prestigious award commends the distinguished service, significant achievement, and positive economic impact of individuals to the state […]
Pfizer and Arena Pharmaceutical on Dec. 13 announced that the companies have entered into an agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per […]
Sumitomo Dainippon Pharma Oncology (SDP Oncology), which has research facilities in Lehi, Utah, recently announced that the first patient has been dosed in a Phase 1 study evaluating its investigational agent DSP-0390, an emopamil-binding protein (EBP) inhibitor, for the treatment of patients with recurrent high-grade glioma. “Dosing the first patient in this study represents another […]
MMV, a Salt Lake City-based seed-stage venture capital firm, announced the first close of its second fund, MMVII. The fund will be managed by Managing Partners Branden Rosenhan, MD, Saumitra Thakur, MD and General Partner and COO Katelin Roberts. “95% of our first fund investors have joined us in MMVII, many stepping up their commitments. […]
On June 8, Altitude Lab has announced the launch of its Investor Coalition, a partnered network of leading healthcare venture capitalists to fund, mentor, and provide resources for Altitude-incubated startups. Together, the investor coalition aims to collectively invest $50 million in Altitude’s startups over the next three years, specifically supporting diverse and underrepresented founders. In […]
Scientia announced it has raised $50M in growth equity financing from Vivo Capital, a Palo Alto, CA-headquartered global healthcare investment firm. The financing will be used to accelerate sales, marketing, and new product development in both its core neurovascular stroke market as well as adjacent markets in peripheral vascular and interventional oncology. “We are excited […]
RenalytixA has announced results from a new utility study. The study confirms the importance of risk assessment testing in addressing treatment ambiguity in the early stages of diabetic kidney disease (DKD) and improving patient engagement and adherence – two major barriers to slowing or preventing DKD progression and preserving kidney health. In clinical studies, KidneyIntelX […]
Turner Imaging Systems has received its CE Mark for its Smart-C ® Mini C-Arm portable fluoroscopy x-ray imaging device. This will allow the Smart-C, the world’s first highly portable mini c-arm, to be distributed throughout the EU countries as well as the UK. “Securing the CE Mark is a critical regulatory milestone and major step […]
Recursion Pharmaceuticals, Inc. today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion is offering 24,242,424 shares of its Class A common stock. The gross proceeds from the offering are expected to be $436.4 million. The shares are expected to […]